Speaker
Dr. Melba Simon
Innovation Program Manager, The Medicine Accelerator
Enantiomer Separation: A Hidden Driver of Process Efficiency
Learn how breakthrough crystallization strategies are reshaping yield, purity, and scalability in drug development.
The pharmaceutical industry faces a recurring challenge: high-potential chiral compounds that stall in development due to inefficient separation techniques. While enantiomer purity is non-negotiable, the prevailing approach often overlooks a key lever—Diastereomeric Salt Crystallization, enabled by Crystallization-Induced Diastereomeric Transformation (CIDT).
In this on-demand technical presentation, The Medicine Accelerator reframes how organizations can think about chiral resolution—not as a constraint, but as a source of speed, savings, and strategic advantage.
Our innovation team shares the science, systems, and scale-up strategies behind CIDT, making a clear case for its impact on yield, cost, and downstream manufacturability.
Key Learnings
This presentation will explore key topics including:
Why traditional chiral separation is failing modern development goals—and how CIDT solves for scale.
How crystallization variables—solvent systems, solubility curves, and counterions—can be tuned to unlock efficiency.
How early-stage crystallization design can influence timelines, cost structures, and CMC readiness.
Who Should Watch
R&D and process scientists looking to improve chiral separations
Technical leads aiming to optimize late-stage scale-up
Business leaders focused on reducing COGs and de-risking development